key: cord-0888415-7i1tss4p
authors: Su, Qiudong; Zou, Yening; Yi, Yao; Shen, Liping; Ye, Xiangzhong; Zhang, Yang; Wang, Hui; Ke, Hong; Song, Jingdong; Hu, Keping; Cheng, Bolin; Qiu, Feng; Yu, Pengcheng; Zhou, Wenting; Cao, Lei; Bi, Shengli; Wu, Guizhen; Gao, George Fu; Zheng, Jerry
title: Recombinant SARS-CoV-2 RBD molecule with a T helper epitope as a built in adjuvant induces strong neutralization antibody response
date: 2020-08-26
journal: bioRxiv
DOI: 10.1101/2020.08.21.262188
sha: 12e84c6f882de7c30aa7b6ca4fe713f45abd7b7e
doc_id: 888415
cord_uid: 7i1tss4p

Without approved vaccines and specific treatment, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is spreading around the world with above 20 million COVID-19 cases and approximately 700 thousand deaths until now. An efficacious and affordable vaccine is urgently needed. The Val308 – Gly548 of Spike protein of SARS-CoV-2 linked with Gln830 – Glu843 of Tetanus toxoid (TT peptide) (designated as S1-4) and without TT peptide (designated as S1-5), and prokaryotic expression, chromatography purification and the rational renaturation of the protein were performed. The antigenicity and immunogenicity of S1-4 protein was evaluated by Western Blotting (WB) in vitro and immune responses in mice, respectively. The protective efficiency of it was measured by virus neutralization test in Vero E6 cells with SARS-CoV-2. S1-4 protein was prepared to high homogeneity and purity by prokaryotic expression and chromatography purification. Adjuvanted with Alum, S1-4 protein stimulated a strong antibody response in immunized mice and caused a major Th2-type cellular immunity compared with S1-5 protein. Furthermore, the immunized sera could protect the Vero E6 cells from SARS-CoV-2 infection with neutralization antibody GMT 256. The candidate subunit vaccine molecule could stimulate strong humoral and Th1 and Th2-type cellular immune response in mice, giving us solid evidence that S1-4 protein could be a promising subunit vaccine candidate.

(C). S1-4 protein purified by ion-exchange chromatography (IEX). (D). S1-4 protein 4 purified by hydrophobic interaction chromatography (HIC) and renaturation. 5 1. Negative control; 2. Non-induced expression bacteria; 3 -4, Induced expression 6 bacteria; 5. Total bacterial proteins after large-scale expression; 6. Soluble fraction of 7 bacterial sonication; 7. Insoluble aggregates of bacterial sonication; 8. S1-4 protein in 8 Urea solution; 9. Unbound fraction eluted by IEX; 10. S1-4 protein fraction eluted by 9 HIC; 11. Re-natured S1-4 protein after stepwise dialysis. 10

After diluted with normal saline, S1-4 protein was mixed with aluminum adjuvant 11 and adjusted antigen concentration in the final adsorption product was 800 μ g/mL. 12

The antigenicity of S1-4 protein was demonstrated by WB analysis with a 2 commercial recombinant RBD protein (Sino Biological, Beijing, China) as positive 3 control ( Figure 2 ). Whether it was convalescent serum of COVID-19 patients ( Figure 2B) , 4

Rabbit monoclonal antibody against RBD ( Figure 2C ) or Rat polyclonal antibody against 5 inactivated SARS-CoV-2 ( Figure 2D ) as the primary antibody, there was an obvious 6 band at about 30 kDa, suggesting the high antigenicity of S1-4 protein. 

caused a major Th2-type cellular immunity 16

To analyze the immunogenicity of SARS-CoV-2 candidate subunit vaccine, we 17 determined the anti-SARS-CoV-2 antibody titers in sera of immunized mice by Enzyme 18 8 Linked Immunosorbent Assay (ELISA) ( Figure 3A ). The total antibody GMT in mice 1 immunized with S1-4 protein/Alum came to 100 one week after the first injection, while 2 it climbed to 1481 one week after the second injection. However, the total antibody GMT 3 in mice immunized with S1-5 protein/Alum was only 24 after the first injection and 192 4 after the second injection. Finally, one week after the third injection, the total antibody 5 GMT in mice immunized with S1-4 protein/Alum was 1728, while that of S1-5 6 protein/Alum was 456. Obviously, S1-4 conjugated with TT peptide tail were more 7 immunogenic than S1-5 without TT peptide. 8

Enzyme-linked Immunospot (ELISpot) assay was applied to enumerate Spot-forming 9 cells (SFCs) for IL-4 and IFN-γ in splenocytes of immunized mice ( Figure 3B ). More IL-10 4 SFCs existed in splencytes of mice immunized with S1-4 protein/Alum comparing with 11 mice immunized with S1-5 protein/Alum (P < 0.05). Meanwhile, there were more IFN-γ 12 SFCs in splencytes of mice immunized with S1-4 protein/Alum than that of S1-5 13 protein/Alum (P < 0.05). These results indicated that not only Th1 (IFN-γ) but also Th2 14 (IL-4) SFCs were involved in the immune response against S1-4 protein/Alum and S1-5 15 protein/Alum. Remarkably, both IL-4 and IFN-γ SFCs were more in mice immunized 16 with S1-4 protein/Alum than those in mice immunized with S1-5 protein/Alum. 

The virus neutralizing activity of SARS-CoV-2 subunit vaccine immunized mice was 6 examined using live SARS-CoV-2 operating within Biosafety Level 3 (BSL-3) 7 Laboratory ( Figure 3A ). The neutralization antibody GMT were 192 on Day28 and 8 reached 256 on Day35 in the sera of mice immunized with S1-4 protein/Alum. However, 9 the neutralization antibody GMTs of sera of mice immunized with S1-5 protein/Alum 1 were only 48 and 64 on Day28 and Day35, respectively. Furthermore, neutralization 2 antibody GMT increased along with total antibody GMT, whether in S1-4 or S1-5 protein 3 immunized mice (P < 0.05). Those results indicated that TT peptide could not only 4 enhance the total antibody response, but also the neutralization antibody. Asn343) and O-linked (Thr323 and Thr385) glycosylation sites within Val308 -20 Gly548 29 . It was presumed that glycosylations at those sites of RBD were not crucial for 21 maintance of antigenicity and immunogenicity of it 8 . In this study, S1-4 protein without 22 glycosylation displayed ideal antigenicity ( Figure 2 ) and immunogenicity (Figure 3) . 23

Moreover, glycosylation and mature structure might hinder the recognition of related 1 epitopes by immune cells. We found that anti-S1-4 protein antibody titers (unpublished) 2 were much higher than anti-SARS-CoV-2 antibody titers. Secondly, the existence of four 3 pairs of cysteine brings great difficulties to the reconstruction of natural structure 8 . 4

Fortunately, our previous experience of SARS-CoV RBD renaturation facilitated the 5 current work 30 . 6

Humoral immune response, especially the neutralization antibody response, plays an 7 important role by limiting infection at later phase and prevents reinfection in the future 12 . 8 S1-4 protein can induce high titer neutralizing antibody. One week after the third 9

immunization, anti-SARS-CoV-2 antibody GMT detected by ELISA reached 1728 while 10 neutralization antibody GMT came to 256 measured by micro-neutralization assay 11 ( Figure 3A ). In contrast, S1-5 protein without TT peptide was barely satisfactory. 12 SARS-CoV-2 maybe induce delayed type I IFN and miss the best time for viral 13 control in an early phase of infection 12 . In general, Th1-type immune response is crucial 14 in an adaptive immunity to eliminate viral infection 12 . The Th1 cells produce cytokines 15 that promote cell-mediated immune responses such as IFN-γ whilst the Th2 cells induce 16 cytokines such as IL-4, IL-5 and IL-13, which will activate humoral immune responses 31 . 17

Current evidences strongly indicated that Th1 type response is a key for successful 18 control of SARS-CoV and MERS-CoV and probably is true for SARS-CoV-2 as well 12 . 19

According to the ELISpot assay, S1-4 protein/Alum could stimulate Th1 and Th2 -type 20 immune responses simultaneously in mice ( Figure 3B ). Furthermore, TT peptide played 21 an important role in promoting cytokine secretion including Th1 and Th2-type cytokines 22

( Figure 3B ). 23

Protective efficacy is crucial for a vaccine. Neutralization activity of immune serum 1 is often the key to judge whether a candidate vaccine will be successful or not. The serum 2 from mice immunized with S1-4 protein/Alum could protect Vero E6 cells from SARS-3

CoV-2 infection with neutralization antibody GMT 256 on Day35 ( Figure 3A) . 4

In conclusion, our preparation of trunked RBD protein fused TT peptide could 5 stimulate humoral and Th1 and Th2-type cell-mediated immune response in mice and 6 the immunized sera could protect Vero E6 cells from SARS-CoV-2 infection. This would 7 make this subunit protein ideal vaccine candidate. 8

The SARS-CoV subunit antigen, designated as S1-4, consisted of the truncated Spike 11 protein Val308 -Gly548 (GenBank No. YP009724390) and TT peptide Gln830 -12

Glu843 with GGG as the linker (Figure 4) . The gene encoding S1-4 protein was codon-13 optimized and sub-cloned into pET28a (+) vector using restriction endonucleases (NcoI After diluted with normal saline, S1-4 protein was mixed with aluminum adjuvant in a 17 certain proportion for adsorption, and the antigen concentration in the final adsorption 18 product was adjusted to 800 μ g/mL. The mixture is designated as SARS-CoV-2 subunit 19 vaccine. 20

The prokaryotic expression and chromatography purification of S1-5 protein were 21 performed according to those of S1-4 protein. The MW of S1-5 was approximately 27.4 22 kDa. Similarly, S1-5 was adjuvanted with Aluminum as a control. 23

All animal procedures were reviewed and approved by the Animal Care and Welfare 2 Committee at the National Institute for Viral Disease Control and Prevention, Chinese 3

Center for Disease Control and Prevention (No. 20200201003). The neutralization tests 4 were performed in a BSL-3 laboratory. Ten specific pathogen-free, female 4~6 weeks old 5 BALB/c mice (Vital River Laboratories, Beijing, China) each group were immunized 6 i.m. with 50 μ L of S1-4/Aluminum, S1-5/ Aluminum or Aluminum alone respectively, 7 with two booster shots at Day 7 and 14. Orbital venous blood was sampled at regular 8 intervals (Day 0, 14, 28 and 35) and sera was collected by centrifugation (1,000 g, 10 min, 9 4°C) after coagulation at room temperature for 2 h. 10 ELISA was applied to evaluate the antibody response according to the previous 11 study 32 . Anti-SARS-CoV-2 antibody titers were determined by an endpoint dilution 12 ELISA on micro-well plates coated with inactivated SARS-CoV-2 viral culture (30 13 ng/well). Briefly, sera serially diluted in phosphate-buffered saline (PBS) were added into 14 micro-well plates (100 μ L/well) and incubated at 37°C for 1 h. Goat anti-mouse IgG 15 antibody (HRP conjugate) (Sigma-Aldrich, SL, USA) was used as the detection antibody 16 (100 μ L/well). Color reaction was developed with 3, 3', 5, 5'-tetramethylbenzidine (TMB) 17 and terminated with H 2 SO 4 solution. The absorbance was read at 450 nm with an ELISA 18 reader (Thermo Fisher, Mannheim, Finland). Antibody titers were determined as the 19 highest dilution at which the mean absorbance of the sample was 2.1-fold greater than 20 that of the control serum. 21

The neutralization antibody titers were detected by a traditional virus neutralization 2 assay using SARS-CoV-2. The assay was performed in quadruplicate, and a series of 3 eight two-fold serial dilutions of the plasma or serum were assessed. Briefly, 100 tissue 4 culture infective dose 50 (TCID 50 ) units of SARS-CoV-2 were added to two-fold serial 5 dilutions of heat-inactivated serum (60°C, 30 min), and incubated for 1 h at 37°C. The 6 virus -serum mixture was added to Vero E6 cells (3×10 5 /well) grown in an ELISpot 7 plate and incubated for 3 d. The endpoint of the micro-neutralization assay was 8 designated as the highest serum dilution at which all three, or two of three, wells were not 9

protected from virus infection, as assessed by visual examination. The neutralizing titers 10 of the dilutions of sera were measured with the maximum dilution achieving the median 11 neutralization 33 . 12

Mouse IFN-γ and IL-4 ELISpot assay were conducted according to the 14 manufacturer's guidelines (DaKeWe, Shenzhen, China). Briefly, splenocytes (3×10 5 per 15 well, in triplicate) of immunized mice at Day35 were plated into ELISpot plate and 16 stimulated with PHA (Positive control) or S1-4 protein. After incubation for 16 h in a 17 37°C humidified incubator with 5% CO 2 , the cells were removed before adding the 18 detection antibody (biotin conjugate). Two hours later at room temperature (RT), 19

Streptavidin-HRP was added after washing plate. One hour later at RT, TMB substrate 20 was applied until distinct spots emerged. Count spots in an ELISpot reader after stopping 21 color development with deionized water. 22

Antibody titers were log-transformed to establish geometric mean titers (GMT) for 2 analysis. The number of specific IFN-γ-or IL-4-secreting T cells were expressed as spots 3 forming cells (SFCs) per 3 × 10 5 cells. The related data were statistically analyzed by 4

Mann-Whitney U test for non-parametric data and the paired t test for parametric data. 5 SPSS software (22.0, Chicago, IL, USA) and GraphPad Prism software (8.00, San Diego, 6 CA, USA) was applied to analyze the data and draw graphics, respectively. Significance 7 was indicated when value of P < 0.05. 8

This work is supported by a project funded by Denogen (Beijing) Biotechnology Co., Ltd. 2

We thank Mrs Jianrong Cao especially for the funding. The funder has no role in study 3 design, data collection and analysis, decision to publish, or preparation of the manuscript. Q.S. and S.B. wrote the paper. All authors read, revised and approved the manuscript. 9

The authors declare that they have no known competing financial interests or personal 11 relationships that could have influenced the work reported in this paper. 12 13

COVID-19: a review. Monaldi archives 2 for chest disease = Archivio Monaldi per le malattie del torace

Coronavirus disease (COVID-19) Situation Report -4 205

A Novel Coronavirus from Patients with Pneumonia in China

The COVID-19 epidemic. Tropical medicine & 10 international health

A pneumonia outbreak associated with a new coronavirus of 12 probable bat origin

Genomic characterisation and epidemiology of 2019 novel 14 coronavirus: implications for virus origins and receptor binding

The SARS-CoV-2 Vaccine 17 Pipeline: an Overview

The biological characteristics of SARS-CoV-2 spike protein 19

Coronaviruses and SARS-CoV-2: A Brief Overview

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2

Structural basis of receptor recognition by SARS-CoV-2

Immune responses in COVID-19 and 6 potential vaccines: Lessons learned from SARS and MERS epidemic

Immunoinformatics-guided designing of epitope-based subunit vaccines against 10 the SARS Coronavirus-2 (SARS-CoV-2)

Immunoinformatic Analysis of T-and B-Cell Epitopes for SARS-12

CoV-2 Vaccine Design

Immune and bioinformatics identification of T cell and B 14 cell epitopes in the protein structure of SARS-CoV-2: A systematic review

Immunogenicity and safety of a novel tetanus toxoid-conjugated anti-17 gastrin vaccine in BALB/c mice

Enhanced epitopic response to a synthetic human malarial peptide 19 by preimmunization with tetanus toxoid carrier

Reduces Immune Enhancement. bioRxiv : the preprint server for biology (2020). Total bacterial proteins after large-scale expression; 6. Soluble fraction of bacterial sonication; 7. 7Insoluble aggregates of bacterial sonication; 8. S1-4 protein in Urea solution; 9. Unbound 8 fraction eluted by IEX; 10. S1-4 protein fraction eluted by HIC; 11. Re-natured S1-4 protein after 9 stepwise dialysis.